We appreciate the comments by Devakumar et al. 1 and agree that there are still some unanswered questions regarding the long-term impact of multiple micronutrient supplementation (MMS) during pregnancy. However, in their assessment, Devakumar and colleagues ignore the significant benefits shown in the individual patient data (IPD) metaanalysis, which strongly influenced our task force's conclusions. Rather, their comments focus only on the birth size data from the Cochrane reviews. 2,3 In the IPD meta-analysis, which included data from nearly 113,000 pregnancies, the authors found that, in addition to reducing the risk of low birthweight, MMS significantly reduces the risk of preterm birth a Formerly at UNICEF, New York, New York.
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(RR = 0.93 (0.87-0.98), random effects). 2 The Cochrane review also states that MMS "probably led to a slight reduction in preterm births" on the basis of data from 91,425 participants with moderate quality evidence (RR = 0.95 (0.90-1.01)). 3 One of the greatest strengths of an IPD metaanalysis is the ability to include predefined subgroup analyses that are based on the individual data, rather than trial-level aggregate data. The meta-analysis in the Cochrane review only used the latter. In the IPD meta-analysis, the authors found that MMS (compared with iron and folic acid supplementation) significantly reduced neonatal mortality among female infants (RR = 0.85 (0.75-0.96)), and had similar significant effects on 6-month and infant mortality, with no effect among males, and reduced 6-month mortality (RR = 0.71 (0.60-0.86)) among all infants doi: 10.1111/nyas.14271 born to anemic mothers. 2 The subgroup analyses also showed that the benefit of MMS with regard to reducing the risk of preterm birth (RR = 0.84 (0.78-0.91)) was greater among infants born to underweight mothers than among those born to women who were not underweight. The global prevalence estimates of underweight (>200 million women of reproductive age) 4 and anemia (>528 million women of reproductive age) 5 are very high, and prevalence rates are highest in low-and middleincome countries, where these MMS trials took place. Thus, in such settings, MMS is likely to benefit a substantial proportion of infants. The potential benefits of MMS for women who are depleted in nutrients other than iron and folate also merit further exploration.
In addition to the short-term benefits of MMS with regard to birth outcomes, the likely longer term consequences of reducing low birthweight and preterm birth should be considered. Low birthweight infants are at an increased risk of death not just during infancy but throughout life, and low birthweight is also associated with reduced lung capacity and immune function as well as an increase in certain cancers. 6 Reducing low birthweight rates remains a World Health Assembly target, and interventions that can reduce the risk of low birthweight, such as MMS, should be encouraged.
More information would be useful regarding the long-term benefits or consequences of all prenatal interventions. For MMS, the evidence continues to accrue from long-term follow-up of trial participants. We note that the Devakumar et al. standard aggregated data meta-analysis includes mortality and anthropometric data for follow-up periods ranging from 6 months to 9 years after birth and combines studies that did and did not continue nutritional interventions after birth, making direct comparisons across studies difficult. 7 Moreover, there is a risk of bias in the existing evidence from follow-up studies because of loss to follow up due to mortality. Valid and reliable cognitive assessments in very young children remain a challenge, which reduces the likelihood of detecting intervention group differences; a much wider array of assessments can be conducted among older children and adults. Recent results on adolescent cognition from a study in rural Western China are encouraging (and appear to have been overlooked by Devakumar et al. in their letter). 8 In that study, which included more than 2,100 14-year olds, the investigators found that children whose mothers received MMS during pregnancy had a dosedependent improvement in intellectual development. The findings of that study are similar to those of the follow-up study of school-age children in the Indonesian SUMMIT study at 9-12 years of age. 9 On the basis of the evidence provided by the Cochrane review and the IPD meta-analysis, the task force is of the opinion that there is sufficient evidence to inform policy decisions now, without waiting for more evidence on long-term outcomes. We agree with Devakumar et al. that improving health outcomes through nutrition interventions requires a life-course approach. MMS is just one intervention during one phase of the life course, and pregnant women in food-insecure situations may need improved macro-as well as micronutrient intake. That said, in populations at risk, MMS during pregnancy can allow infants to begin life with a significant advantage.
